Avacta continues to enroll patients in the Phase 1b expansion cohorts with data in salivary gland cancer anticipated by the end of 2025.

RAPT will host a webcast conference call accompanied by a slide presentation on Monday, October 20, 2025 at 8:30 a.m. ET. To join the conference call via phone and participate in the live Q&A session, ...

New findings from this investigational study build on the strength of the data for amivantamab in non-small cell lung cancer and broadens its potential across additional solid tumours 1,2 “Patients ...

Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium ( 177 Lu) vipivotide tetraxetan) data from the Phase III PSMAddition trial in a Presidential Symposium at the European Society ...

The analysis of acral melanoma patients from the IGNYTE clinical trial showed treatment with RP1 combined with nivolumab resulted in an objective response rate of 44% (8/18) with a median duration of ...

Revenue growth for the September 2025 quarter compared with the June 2025 quarter was driven by a 66% increase in Ryoncil ® gross sales to US$21.9 million and 69% increase in net sales to US$19.1 ...

BOSTON, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Precede Biosciences, a company advancing precision medicine through its first-in-class comprehensive epigenomic liquid biopsy platform, today announced the ...

The data represent the first clinical trial results of a 212Pb-based PSMA therapy. The findings support the further development of 212Pb-ADVC001 and may offer a new reference point in the treatment ...

Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S ®), an investigational folate receptor alpha ...

Earlier this month, Company CEO Ryoji Baba was officially invited by the Embassy of Japan in Vietnam and appointed as a Board Member of United Nations-affiliated non-governmental organization (“NGO”) ...

Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups ; Median PFS was 15.5 months in the 120 mg palazestrant cohort ...

ART6043 continues to be evaluated in a first-in-human Phase 1/2a study in patients with advanced solid tumors. ART6043 has the potential to advance into dedicated Phase 2 trials to assess efficacy ...